Objective: Given that the Women's Health Initiative reported in 2002 increased risks of breast cancer and cardiovascular events with hormone therapy (HT) use and many women discontinued use, we assessed the use and perceived efficacy of complementary and alternative medicines (CAMs) for menopausal symptom relief after discontinuation of HT.
W omen may experience significant vasomotor, sexual, psychological, and somatic symptoms during the menopausal transition. 1 Vasomotor symptoms (VMS)Vhot flushes and night sweatsVare the most common, 2 with one in two postmenopausal women reporting them to be troublesome. 3 A meta-analysis indicated that they often persist several years after menopause, 4 compromising quality of life and disrupting women's sense of well-being. 5 Hormone therapy (HT) is the most effective treatment of VMS. It reduces frequency and severity by 75% 6 and improves health-related quality of life. 7 However, HT use has been in decline since 2002, 8 when the Women's Health Initiative (WHI) 9 reported increased risks of breast cancer and cardiovascular events in women using HT. This decline has been associated with increasing use of complementary and alternative medicines (CAMs) for relief of menopausal symptoms. 10 CAMs are a Bdiverse group of medical and health care systems, practices and products that are not generally considered to be part of conventional medicine.[ 11 Although the popularity of CAMs is high among women, there is little evidence to support their use in the control of menopausal symptoms. The efficacy data of herbal remedies and phytoestrogens have so far been inconclusive. Only black cohosh has been investigated systematically in randomized trials, and a Cochrane review has concluded that there is insufficient evidence to support its use. 10, 12 We report on the use and perceived benefits of CAMs for relief of VMS in women who discontinued HT after the WHI report, using a nested cohort design within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
METHODS

Study participants
The UKCTOCS is a randomized controlled trial (RCT) assessing the impact of screening on ovarian cancer mortality. Between April 2001 and October 2005, 202,638 apparently healthy postmenopausal women aged 50 to 74 years were recruited to the trial through 13 regional trial centers located in NHS Trusts in England, Wales, and Northern Ireland and randomized to annual screening with (1) serum CA125, interpreted using the BRisk of Ovarian Cancer[ algorithm (multimodal group, n = 50,640); (2) transvaginal ultrasound (ultrasound group, n = 50,639); or (3) control (no screening, n = 101,359). 13 Postmenopausal status in these women was defined as more than 12 months of amenorrhea after natural menopause or hysterectomy with ovarian conservation or more than 12 months of HT commenced for menopausal symptoms. The study was approved on 
Survey
At recruitment, all women completed a baseline datasheet regarding reproductive and lifestyle factors and current HT use. Three to 5 years after randomization, the women were sent a postal follow-up questionnaire (FUQ). In addition to lifestyle factors and medical history, the women were asked about their current use of HT. Beginning July 2006, women completing the FUQ were also asked whether they had used any nonhormonal treatments to alleviate menopausal symptoms and if they would be willing to take part in a detailed survey of how women deal with menopause. Women aged 50 to 65 years at FUQ completion who agreed to participate were sent the Bmanaging menopausal symptoms[ (MMS) survey. This included questions about any menopausal symptoms they experienced and severity (rated as "bothersome" on a scale from 1 to 10) HT use (ever/current use), reasons for use (eg, hot flushes, vaginal dryness, tiredness), and perceived helpfulness for relief of hot flushes and night sweats. Those who had discontinued HT were asked to select reasons for discontinuation, to list any symptoms they had experienced since stopping (eg, VMS), and if they had used any other therapies/treatments for relieving VMS. The latter were broadly grouped into three categories: (1) herbal/homeopathic remedies or over-thecounter medicines (eg, black cohosh, evening primrose oil, phytoestrogens); (2) behavioral/lifestyle approaches (eg, regular exercise, yoga, counseling, and cognitive-behavioral therapy [CBT]); or (3) other prescribed medical treatmentsVselective serotonin reuptake inhibitors (SSRIs; eg, fluoxetine, paroxetine, sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs; eg, venlaflaxine), antihypertensive drugs (eg, clonidine), progestogens (eg, megestrol acetate), or antiepileptic drugs (eg, gabapentin). For the purposes of this analysis, CAMs included Bherbal/homeopathic remedies or over-the-counter medicines[ and Bbehavioral/lifestyle approaches,[ whereas Bmedical treatments[ included all other prescribed treatments. As there have been a number of studies examining the effects of exercise on VMS relief, 14, 15 we included exercise in behavioral/lifestyle approaches that women may use for relief of menopausal symptoms even though it does not fall strictly under the definition of BCAM.[ The women were asked to rate the level of helpfulness with regard to relief of symptoms on a scale from 1 to 10 (1, Bno effect[; 10, Bmost helpful[). For this analysis, treatments were considered to be helpful in relieving VMS if they were rated 7 or higher (most effective) or 4 to 6 (moderately effective) on the Bhelpfulness[ scale (1 to 3 on the scale was considered minimally effective/ineffective).
Statistical analysis
Descriptive statistics were used to summarize the results according to HT use, reasons for use of HT, reasons for stopping HT, use of CAMs, and perceived helpfulness of CAMs.
RESULTS
Between July 2 and July 9, 2008, 15,000 UKCTOCS participants aged 50 to 65 years who agreed to participate in the MMS survey were sent the survey. Overall, 10,662 (71.1%) returned the questionnaire. Fifty-five were excluded because of errors in their study reference number (unique identifier). The remaining 10,607 (70.7%) had complete data and were included in the analysis. The baseline characteristics of responders and nonresponders were very similar ( Table 1 
Prevalence and severity of menopausal symptoms
When women were asked about symptoms they had experienced during the menopausal transition (Table 1) , most reported hot flushes (80.6%; 8,544 of 10,607) and night sweats (72.5%; 7,690 of 10,607). Severe (Q7) symptoms were reported by almost three quarters (73.5%; 7,795 of 10,607) of women, with the most severe being night sweats (42.0%; 4,460 of 10,607), hot flushes (41.9%; 4,443 of 10,607), sleep difficulties (37.6%; 3,987 of 10,607), and tiredness/fatigue (29.2%; 3,094 of 10,607). Only 1.9% (197 of 10,607) of women reported no symptoms at all.
HT use
Overall, 60.2% (6,383 of 10,607) of women reported ever use of HT, of whom 12.3% (1,300 of 10,607) reported that they were still using it at the time of completion of the MMS survey. Of those reporting ever use of HT, 74.8% (4,776 of 6,383) took HT because they experienced hot flushes, night sweats, and sleep difficulties ( Table 2) . Changes in mood (40.1%; 2,557 of 6,383) and tiredness (37.3%; 2,380 of 6,383) were the other reported indications. Although 41.7% (2,663 of 6,383) included prevention of osteoporosis as a reason for having taken HT, only 3.0% (190 of 6,383) reported it as the sole indication. Most women (71.8%; 4,585 of 6,383) used it for multiple reasons. About 83.7% (5,342 of 6,383) of HT users found it to be helpful.
In total, 79.3% (5,060 of 6,383) of HT ever users reported that they had discontinued use. Specifically, 37.5% (2,396 of 6,383) of those younger than 60 years had discontinued use. Over three-quarters (76.7%, 3,883 of 5,060) had discontinued HT because of concerns regarding its safety: doctor's advice, 45.2% (2,287 of 5,060); personal safety concerns, 38.9% (1,969 of 5,060); or media coverage of HT trials, 17.6% (891 of 5,060; Table 3 ).
Upon discontinuation of HT, symptoms recurred in 93.1% (4,712 of 5,060) of women, with more than two thirds (67.9%; 3,437 of 5,060) of women reporting severe (Q7) symptoms. The most commonly reported symptoms continued to be hot flushes (89.3%; 4,521 of 5,060), night sweats (79.5%; 4,025 of 5,060), and sleep difficulties (74.1%; 3,750 of 5,060; Table 4 ). Of the women who discontinued HT, 70.2% were aware that symptoms may recur.
CAMs for relief of VMS in women discontinuing HT
Overall, 42.8% (4,540 of 10,607) of women used CAMs. Of those who had discontinued HT, 89.7% (4,540 of 5,060) reported that they had used one or more CAMs. Use of individual CAMs ranged widely (Fig.) , with regular exercise being most commonly used for relief of VMS (68.2%; 3,098 of 4,540; Table 5 ). Evening primrose oil was the only other option used by half of the women (48.6%; 2,205 of 4,540). Herbal/ homeopathic remedies were used by 69.1% (3,495 We further assessed whether patterns of CAM use differed by age by subdividing the cohort into two groups: women younger than the median age of 59.8 years and women older than 59.8 years. Women who were older than 59.8 years at survey completion reported higher use of all CAMs, except for Menopace (Fig. 1 , Supplemental Digital Content 2, http:// links.lww.com/MENO/A112).
Use of multiple CAM therapies
Overall, 58.6% of women used up to three CAM therapies, with 22.0% (999 of 4,540) using one CAM therapy, 18.9% (883 of 4,540) using two CAM therapies, and 58.5% (2,658 of 4,540) using three or more CAM therapies ( Table 2 , Supplemental Digital Content 1, http://links.lww.com/MENO/A111). The latter included 39.0% (1,362 of 3,492) using three or more herbal remedies and 29.5% (1,100 of 3,727) using three or more lifestyle approaches.
Self-reported effectiveness
All behavioral/lifestyle approaches were rated to be effective by at least half of the women (rating Q4; 
Recommend use of CAMs to other women
Of those who used CAM remedies, few would recommend their use to other women. The most recommended CAMs were phytoestrogens (16.5%; 188 of 1,137) and evening primrose oil (11.0%; 242 of 2,205), followed by black cohosh (8.0%; 110 of 1,377; data not shown).
Medical treatments for relieving VMS in women discontinuing HT
Women were also asked whether they had used any other medical treatments (SSRIs, SNRIs, antihypertensive drugs, progestogens, or antiepileptic drugs). Overall, 13.8% (697 of 
DISCUSSION
To our knowledge, this is, to date, the largest study of CAM use in women who have discontinued HT. We are aware of only one other study (based on data from 563 women) that specifically explored CAM use in this population. 17 Our 2008-2009 cross-sectional survey of more than 10,000 British postmenopausal women aged 54 to 65 years showed that most (93.1%) of the women who discontinued HT experienced recurrence of symptoms, with three out of four women reporting severe (rating Q7) symptoms. About 89.7% used CAMs, with most opting for herbal/homeopathic remedies. Importantly, although behavioral/lifestyle approaches, excluding exercise, were used by only 13.9% of women, these were reported to be more effective than herbal/homeopathic remedies. More than two thirds of those who had used mindfulness, massage, meditation/yoga, relaxation, and counseling reported them to be effective (score Q4), compared with less than half of the women using herbal/homeopathic remedies. In keeping with this, few women would recommend use of herbal/ homeopathic remedies to others for relief of menopausal symptoms. The data suggest a disconnect between women's use of herbal/lifestyle CAMs and women's perceptions of their effectiveness after having used them.
In our study, 60% of women reported ever use of HT, similar to the 47.2% reported in the Million Women Study. 18 Most women had used it for multiple reasons, with hot flushes/night sweats (74.8%) being the leading indication. Most (84%) found it helpful for relief of menopausal symptoms, but most (80%) discontinued use, including 37% of women younger than 60 years. The main reasons were doctor's advice, safety concerns, and having heard/read about the results of HT trials. Recently, a Norwegian study also reported on reasons for stopping HT, with 30% of women discontinuing use because of fear of adverse events, 19 similar to the 39% of women in our study reporting this as the main reason. Three out of four women were aware that their symptoms would recur, and over 90% reported recurrence of symptoms upon discontinuing HT, as also reported by the Norwegian study. 19 Until June 2013, guidelines on HT use had recommended that women use HT for the shortest time possible. Despite guidelines now approving the use of HT for VMS up to age 60 years, 20 the impact of the original negative publicity is likely to be long-lasting.
The overall prevalence of CAM use in 2008-2009 (42.8%) in this study is comparable to that (48%) reported on in a meta-analysis in a recent systematic review of CAM surveys. 21 Small differences may be attributable to overrepresentation of US women in the latter and inclusion of studies before the publication of the WHI results in 2002.
Herbal medicine (black cohosh, donq quai, and evening primrose), soy/phytoestrogens (including red clover), relaxation, and yoga were the most commonly used CAMs for menopausal symptom relief in the recent systematic review. 21 Half of the women surveyed reported use of herbal remedies, with evening primrose oil (48.6%), black cohosh (30.3%), and phytoestrogens (25.0%) being most commonly used. However, these were deemed effective (scores Q4) in relieving symptoms by less than half of the women surveyed. Despite a third of the women using black cohosh, more than two thirds reported minimal effectiveness. Although many used herbal/ homeopathic remedies, few (phytoestrogens, 16.5%; evening primrose oil, 11.0%; black cohosh, 8.0%) would recommend these to other women.
Interestingly, nearly three quarters of the women reported use of exercise as the approach of choice, with symptom relief in 70%. The other lifestyle approaches, although used by fewer women, were perceived as more effective than herbal remedies. Interestingly, RCTs have not confirmed exercise to be effective in alleviating VMS 15, 22 but have reported that it may improve sleep and depression in postmenopausal women. 14 Mindfulness has been shown to reduce distress and bother from VMS compared with a wait-list control in an RCT. 23 Furthermore, a recent prospective cohort study of 6,040 women comparing two diet methods found Mediterranean-style diet to be associated with fewer VMS. 24 The treatments women reported to be most effective (scores Q7) were counseling (38%), massage (36%), and CBT (35%), consistent with previous findings suggesting that psychoeducational interventions alleviate VMS. 25 A recent RCT showed that CBT significantly reduces problem ratings associated with VMS and the frequency of night sweats 26 and that CBT can be delivered with little health professional time. 27 Furthermore, CBT, whether delivered in a group or in self-help format, is effective in reducing the impact of VMS. 28 In our study, few women used medical treatments other than HT to relieve their VMS, with only 10% having used SSRIs/SNRIs and with less than 5% having used antihypertensive drugs, progestogen, or antiepileptic drugs. SSRIs have consistently been reported, although with lower efficacy than HT, to reduce the frequency and severity of VMS in RCTs.
29<31
Seventy-two percent of women in our survey also reported SSRIs to be effective, with almost half reporting them to be very effective (scores Q7). Many women use CAMs to alleviate menopausal symptoms, as there is a perception that CAMs are safer and more Bnatural[ than HT. A recent review indicated that 55% of women using CAMs did not disclose this to their medical practitioner 21 even though potentially life-threatening adverse events, such as hepatitis and liver failure, have been reported with use of black cohosh. 32 Many women seek over-the-counter CAMs for menopausal symptom relief. The discrepancy between women's choice of strategies, their perceptions of outcomes, and the current evidence suggests that they would benefit from evidence-based information about the efficacy of these interventions. An earlier US survey of 413 women also suggested that women do not feel sufficiently informed to make decisions regarding CAM options for alleviating menopausal symptoms. 33 A UK National Institute for Health and Care Excellence guidance on the effectiveness of menopausal treatments, which is scheduled to be published in 2015, is therefore most timely.
The main strengths of this study are its size, generalizability (postmenopausal women from the general population across England, Wales, and Northern Ireland), and the survey period 2008-2009, after the main WHI results 9 but before data reanalysis. 34 We add to previous UK surveys that reported CAM use between 2001 and 2006. As all women had previously used HT, we believe that the efficacy of HT provided them a useful reference for evaluating the effectiveness of CAMs in relieving VMS. We also asked women which CAMs they would recommend to other women, which we thought was a good indicator of their overall experience with CAM use. Our study is in keeping with most other studies that focused on relief of vasomotor menopausal symptoms, which women find the most distressing. There is currently a lack of evidence for management strategies for menopausal symptoms in women who have discontinued HT, and our study may provide useful guidance/information regarding the use of alternative therapies for symptom relief. As Espen Gjelsvik et al 19 indicated, despite experiencing significant VMS, women tend to prefer to live without HT, suggesting that women are still concerned about the safety and adverse events associated with HT use.
Limitations include the cross-sectional design of the study and the possibility that the women who took part in the MMS survey may have been more likely to have severe menopausal symptoms and therefore more likely to try various treatment modalities. In keeping with all previous surveys, there is inherent bias related to self-selection. There is a possibility of recall bias. In addition, it is probable that women who had troublesome (97) symptoms were more likely to have completed the survey. However, the prevalence of self-reported severe symptoms (73.5%) in our study is in keeping with previous reports. 35 Our questionnaire did not collect data on exact formulation, dose, adverse events related to CAM use, or concurrent use of multiple CAM treatments. The survey included an exhaustive list of CAM therapies. There may be newer therapies for VMS relief that women may have tried since. The participants were mainly white; therefore, we are unable to report on use among other ethnic groups. We did not examine the relationship between HT/CAM use and variables such as education, income, and smoking, which have previously been shown to influence a woman's decision-making regarding uptake of these therapies.
CONCLUSIONS
Although more women use over-the-counter medicines, they report behavioral/lifestyle approaches to be more effective in alleviating VMS. This suggests the need for more readily available evidence-based information to support women's decision-making.
